Table 2. Longitudinal High-Sensitivity C-Reactive Protein Levels and Clinical Outcomes: Univariate Analysis.
| Outcome | Hazard Ratio (95% CI)a | P Value |
|---|---|---|
| Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina at 16 weeks | 1.16 (1.11-1.22) | <.001 |
| All-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina | 1.16 (1.11-1.22) | <.001 |
| Cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke | 1.19 (1.13-1.24) | <.001 |
| All-cause death | 1.25 (1.19-1.32) | <.001 |
| Cardiovascular death | 1.26 (1.20-1.32) | <.001 |
| Myocardial infarction | 1.16 (1.08-1.25) | <.001 |
| Hospitalization for unstable angina | 1.03 (0.96-1.11) | .39 |
| Stroke | 0.997 (0.85-1.17) | .97 |
a
Hazard ratios and 95% CI per SD unit increase in high-sensitivity C-reactive protein level was calculated using Cox proportional hazards regression models. Models were also adjusted for baseline high-sensitivity C-reactive protein level.